Phosphorylation of TNF-alpha Converting Enzyme by Gastrin-releasing Peptide Induces Amphiregulin Release and EGF Receptor Activation
Overview
Authors
Affiliations
G protein-coupled receptors induce EGF receptor (EGFR) signaling, leading to the proliferation and invasion of cancer cells. Elucidation of the mechanism of EGFR activation by G protein-coupled receptors may identify new signaling paradigms. A gastrin-releasing peptide (GRP)/GRP receptor-mediated autocrine pathway was previously described in squamous cell carcinoma of head and neck. In the present study, we demonstrate that TNF-alpha converting enzyme (TACE), a disintegrin and metalloproteinse-17, undergoes a Src-dependent phosphorylation that regulates release of the EGFR ligand amphiregulin upon GRP treatment. Further investigation reveals the phosphatidylinositol 3-kinase (PI3-K) as the intermediate of c-Src and TACE, contributing to their association and TACE phosphorylation. Phosphoinositide-dependent kinase 1 (PDK1), a downstream target of PI3-K, has been identified as the previously undescribed kinase to directly phosphorylate TACE upon GRP treatment. These findings suggest a signaling cascade of GRP-Src-PI3-K-PDK1-TACE-amphiregulin-EGFR with multiple points of interaction, translocation, and phosphorylation. Furthermore, knockdown of PDK1 augmented the antitumor effects of the EGFR inhibitor erlotinib, indicating PDK1 as a therapeutic target to improve the clinical response to EGFR inhibitors.
ACE2-EGFR-MAPK signaling contributes to SARS-CoV-2 infection.
Engler M, Albers D, von Maltitz P, Gross R, Munch J, Cirstea I Life Sci Alliance. 2023; 6(9).
PMID: 37402592 PMC: 10320016. DOI: 10.26508/lsa.202201880.
NOTCH1 Signalling: A key pathway for the development of high-risk chronic lymphocytic leukaemia.
Edelmann J Front Oncol. 2022; 12:1019730.
PMID: 36313682 PMC: 9606825. DOI: 10.3389/fonc.2022.1019730.
Akiyama N, Yamamoto-Fukuda T, Yoshikawa M, Kojima H Laryngoscope Investig Otolaryngol. 2022; 7(3):730-739.
PMID: 35734041 PMC: 9195017. DOI: 10.1002/lio2.785.
Yang H, Khalil R Adv Pharmacol. 2022; 94:255-363.
PMID: 35659374 PMC: 9231755. DOI: 10.1016/bs.apha.2021.11.002.
Molecular Pathways and Druggable Targets in Head and Neck Squamous Cell Carcinoma.
Kordbacheh F, Farah C Cancers (Basel). 2021; 13(14).
PMID: 34298667 PMC: 8307423. DOI: 10.3390/cancers13143453.